Monashee Investment Management LLC acquired a new stake in shares of Kyverna Therapeutics, Inc. (NASDAQ:KYTX – Free Report) in the fourth quarter, according to its most recent Form 13F filing with the Securities & Exchange Commission. The firm acquired 195,000 shares of the company’s stock, valued at approximately $1,833,000. Monashee Investment Management LLC owned 0.45% of Kyverna Therapeutics as of its most recent filing with the Securities & Exchange Commission.
A number of other hedge funds and other institutional investors also recently made changes to their positions in KYTX. AIGH Capital Management LLC acquired a new stake in shares of Kyverna Therapeutics in the fourth quarter valued at $14,100,000. RFG Advisory LLC acquired a new stake in shares of Kyverna Therapeutics in the fourth quarter valued at $4,185,000. Simplify Asset Management Inc. acquired a new stake in shares of Kyverna Therapeutics in the fourth quarter valued at $1,808,000. Propel Bio Management LLC acquired a new stake in shares of Kyverna Therapeutics in the fourth quarter valued at $6,267,000. Finally, Jefferies Financial Group Inc. increased its stake in shares of Kyverna Therapeutics by 96.3% in the fourth quarter. Jefferies Financial Group Inc. now owns 32,001 shares of the company’s stock valued at $301,000 after buying an additional 15,701 shares in the last quarter. 18.08% of the stock is owned by institutional investors.
Kyverna Therapeutics Price Performance
Shares of KYTX stock opened at $7.87 on Friday. The stock has a 50-day moving average price of $9.00 and a 200 day moving average price of $8.55. The company has a quick ratio of 8.15, a current ratio of 8.15 and a debt-to-equity ratio of 0.13. The firm has a market cap of $478.42 million, a price-to-earnings ratio of -2.40 and a beta of 1.95. Kyverna Therapeutics, Inc. has a 12 month low of $2.52 and a 12 month high of $13.67.
Analyst Upgrades and Downgrades
A number of brokerages have recently weighed in on KYTX. JPMorgan Chase & Co. lowered their target price on Kyverna Therapeutics from $30.00 to $29.00 and set an “overweight” rating for the company in a research note on Wednesday, May 13th. HC Wainwright restated a “buy” rating and issued a $25.00 target price on shares of Kyverna Therapeutics in a research note on Wednesday, June 3rd. Wall Street Zen lowered Kyverna Therapeutics from a “hold” rating to a “sell” rating in a research note on Saturday, May 30th. Finally, Weiss Ratings restated a “sell (d-)” rating on shares of Kyverna Therapeutics in a research note on Friday, March 27th. Five research analysts have rated the stock with a Buy rating and one has issued a Sell rating to the company’s stock. Based on data from MarketBeat, Kyverna Therapeutics currently has an average rating of “Moderate Buy” and an average target price of $30.00.
Read Our Latest Research Report on Kyverna Therapeutics
Kyverna Therapeutics Company Profile
Kyverna Therapeutics is a clinical‐stage biotechnology company dedicated to developing engineered regulatory T‐cell (Treg) therapies for the treatment of autoimmune and inflammatory diseases. Leveraging a proprietary platform for the isolation, expansion and modification of Treg cells, the company aims to restore immune homeostasis in patients by delivering antigen‐specific cell therapies that selectively target diseased tissues while minimizing systemic immunosuppression.
The company’s lead programs include an allogeneic Treg candidate in clinical development for ulcerative colitis, with additional preclinical assets focused on rheumatoid arthritis and other chronic inflammatory conditions.
Featured Stories
- Five stocks we like better than Kyverna Therapeutics
- Microsoft Just Gave Investors 3 Dates They Can’t Afford to Ignore
- NVIDIA’s Outlook Gains Momentum: Stock Price to Follow
- The World Cup Is Coming—These 3 Stocks Could Cash In
- Spotify’s “North Star” Outlook Was Music to Investors Ears
Want to see what other hedge funds are holding KYTX? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Kyverna Therapeutics, Inc. (NASDAQ:KYTX – Free Report).
Receive News & Ratings for Kyverna Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Kyverna Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.
